VACCINEX, INC.
VACCINEX, INC. (VCNX): 4 pipeline candidates · ~1 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.2 months
0% dilution
Lead: Phase 1/Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for VACCINEX, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.7M
Cash
$1.1M
Quarterly Burn
$3.9M
Runway
1.2 mo
Revenue
$213K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Frequently asked questions
How many drug candidates are in VACCINEX, INC.'s pipeline?
VACCINEX, INC. (VCNX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is VACCINEX, INC.'s lead drug candidate?
VACCINEX, INC.'s most advanced tracked candidate is avelumab (Phase 1/Phase 2) for Metastatic Pancreatic Adenocarcinoma.
What is VACCINEX, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, VACCINEX, INC. has approximately 1.2 months of cash runway.
What is VACCINEX, INC.'s market capitalization?
VACCINEX, INC.'s market capitalization is approximately $2.7M.
Who is the CEO of VACCINEX, INC.?
Dr. Maurice Zauderer Ph.D. is the chief executive officer of VACCINEX, INC. (VCNX).
Get the full picture on VACCINEX, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.